Professor Thomas Burris of The Scripps Research center, the biggest nonprofit biomedical research center in the United States with over 1,100 patents and 11 FDA-approved medications, is the original developer of stenabolic, commonly known as SR9009, a synthetic metabolic modulator. Professor Thomas Burris of the Scripps Research Institute created the research medication SR9009, sometimes referred to as Stenabolic, as an agonist of Rev-ErbA. Fatty acid oxidation and glucose metabolism are both enhanced by SR9009. The synthetic Rev-Erb ligand stenabolic, also known scientifically as SR9009, has emerged as a key player in studies on metabolism and endurance. in contrast to SARMs, or selective androgen receptor modulators.
Take 15mg (1 capsule) three times daily with meals for better absorption.Use morning, pre-workout, and evening for continuous metabolic activation.